As of July 6, 2026

Please refer to local prescribing information for more information, including full safety information, on Incyte’s marketed medicines, or on medicines marketed by Incyte’s collaboration partners.

1. Jakafi^® and Jakafi XR^™ are marketed by Incyte in the U.S.; ruxolitinib is licensed to Novartis outside the U.S. and marketed as Jakavi^® 2. Approved in the U.S. 3. Development in collaboration with Merus 4. In collaboration with Syndax 5. Approved in multiple territories, including the U.S., the EU, Canada, and Japan 6. Approved in Japan 7. European rights to ponatinib licensed from Takeda 8. Approved in the EU 9. Licensed from MacroGenics 10. Approved in Canada 11. Worldwide rights to baricitinib licensed to Lilly
12. Approved in multiple territories globally 13. Worldwide rights to capmatinib licensed to Novartis 14. Worldwide rights to zilurgisertib licensed to Mirum 15. IPF study currently led and funded by Syndax

1L, first-line; 3L+, third-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; CALR, calreticulin; DLBCL, diffuse large B-cell lymphoma; ET, essential thrombocythemia; EU, European Union; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IPF, idiopathic pulmonary fibrosis; MLNs, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; mut, mutant; PDAC, pancreatic ductal adenocarcinoma; Ph+, Philadelphia chromosome-positive; r/r, relapsed or refractory; wAIHA, warm autoimmune hemolytic anemia; XR, extended release.